Pharmacogenomic testing in child and adolescent psychiatry: An evidence-based review

Significant advances have been made in the application of pharmacogenomic testing for the treatment of patients with psychiatric disorders. Over the past decade, a number of studies have evaluated the utility of pharmacogenomic testing in pediatric patients with psychiatric disorders. The evidence base for pharmacogenomic testing in youth with depressive and anxiety disorders as well as attention/deficit hyperactivity disorder (ADHD) is reviewed in this article. General pharmacogenomic principles are summarized and functional polymorphisms in P450 enzymes (and associated metabolizer phenotypes), the serotonin transporter promoter polymorphisms, serotonin 2 A receptor genes (e.g., HT2AR) and catecholamine pathway genes (e.g., COMT) are reviewed.
Source: Current Problems in Pediatric and Adolescent Health Care - Category: Pediatrics Authors: Source Type: research